NCT05197153View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

804

Participants

Timeline

Start Date

January 22, 2022

Primary Completion Date

June 1, 2022

Study Completion Date

October 28, 2022

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

Half dose of MVC-COV1901

Approximately 240 participants will receive 1 doses of half of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

BIOLOGICAL

Full dose of MVC-COV1901

Approximately 240 participants will receive 1 doses of MVC-COV1901(S-2P protein with adjuvant) at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

BIOLOGICAL

AZD1222

Approximately 240 participants will receive 1 doses of AZD1222 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

BIOLOGICAL

Half dose of mRNA-1273

Approximately 240 participants will receive 1 doses half of mRNA-1273 at Visit 2 (Day 1) via intramuscular (IM) injection in the deltoid region.

Trial Locations (4)

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

National Taiwan University Hospital, Taipei

Taipei Municipal Wan Fang Hospital, Taipei

Taipei Veteran General Hospital, Taipei

Sponsors
All Listed Sponsors
collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT05197153 - A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 | Biotech Hunter | Biotech Hunter